Skip to main content
SpringerLink
Log in

Hepatitis Viruses: Hepatitis C

  • Chapter
  • First Online:
Viral Infections of Humans

  • 4739 Accesses

Abstract

Hepatitis C virus (HCV), a member of the Flaviviridae family, is a bloodborne pathogen infecting approximately 170 million persons representing around 3 % of the population worldwide, with substantial variability in prevalence in different geographic regions. It is a leading cause of chronic liver disease, cirrhosis, and hepatocellular carcinoma, as well as the most common indication for liver transplantation in many countries. It is a major public health problem and a leading cause of morbidity and mortality. The major route of transmission is via exposure to infected blood, so that infections are commonly seen resulting from transfusions where the blood supply is not screened or the sharing of works by injection drug users. Sexual, perinatal, and occupational injury transmission also occur. Although limited in scope, health-care-related outbreaks have been seen due to poor infection control. While the incidence of HCV infection has decreased during the last several decades, because of the prolonged duration between infection and the development of the major liver-related complications resulting from infection, the prevalence of those complications continues to rise. A minority of persons infected with HCV clears the virus spontaneously; most develop chronic infection. In the USA, it is estimated that three-quarters of infected persons are unaware of their HCV infection. Because HCV infection is most often asymptomatic until the late complications of advanced liver disease, diagnosis of chronic HCV infection usually depends on asymptomatic screening of at-risk individuals or those with elevations of serum transaminases. Among persons with chronic HCV infection, factors associated with more rapid liver fibrosis include older age at time of infection, male gender, obesity, hepatic steatosis, insulin resistance, hepatic iron overload, and coinfection with hepatitis B virus or human immunodeficiency virus. However, not all persons with chronic HCV infection progress to cirrhosis or end-stage liver disease. More than one-third of persons with chronic HCV infection have one or more symptomatic extrahepatic manifestations. Because HCV infection is preventable, it should be a key focus of clinical and public health interventions. Unless a vaccine becomes available, prevention of HCV acquisition depends on minimizing exposure by eliminating transfusion of infected blood products, reducing high-risk behaviors, and optimizing infection control practices. HCV is also treatable, and when successful, infection can be eradicated with elimination of transmission risk for the treated individual. While treatments options are increasing with the recent and ongoing development of oral therapies, optimizing reduction of transmission depends on identifying and treating asymptomatic infected persons as well as those who are ill. It is important to note that cure does not prevent reinfection, since there is no long-term natural immunity to HCV reinfection.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 299.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Hepatitis C. Wkly Epidemiol Rec. 1997;72:65–9.

    Google Scholar 

  2. Hepatitis C–global prevalence (update). Wkly Epidemiol Rec. 2000;75:18–9.

    Google Scholar 

  3. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144:705–14.

    PubMed  Google Scholar 

  4. Lavanchy D. The global burden of hepatitis C. Liver Int. 2009;29 Suppl 1:74–81.

    PubMed  Google Scholar 

  5. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005;5:558–67.

    PubMed  Google Scholar 

  6. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142:1264–73 e1.

    PubMed  PubMed Central  Google Scholar 

  7. El-Serag HB. Epidemiology of hepatocellular carcinoma in USA. Hepatol Res. 2007;37 Suppl 2:S88–94.

    PubMed  Google Scholar 

  8. Verna EC, Brown Jr RS. Hepatitis C virus and liver transplantation. Clin Liver Dis. 2006;10:919–40.

    PubMed  Google Scholar 

  9. Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl. 2003;9:331–8.

    PubMed  Google Scholar 

  10. Institute of Medicine. Hepatitis and liver cancer: a national strategy for prevention and control of hepatitis B and C. Washington, DC: National Academies Press; 2010.

    Google Scholar 

  11. Feinstone SM, Kapikian AZ, Purcell RH, Alter HJ, Holland PV. Transfusion-associated hepatitis not due to viral hepatitis type A or B. N Engl J Med. 1975;292:767–70.

    PubMed  CAS  Google Scholar 

  12. Prince AM, Brotman B, Grady GF, et al. Long-incubation post-transfusion hepatitis without serological evidence of exposure to hepatitis-B virus. Lancet. 1974;2:241–6.

    PubMed  CAS  Google Scholar 

  13. Alter HJ, Purcell RH, Shih JW, et al. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med. 1989;321:1494–500.

    PubMed  CAS  Google Scholar 

  14. Kuo G, Choo QL, Alter HJ, et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science. 1989;244:362–4.

    PubMed  CAS  Google Scholar 

  15. Aach RD, Kahn RA. Post-transfusion hepatitis: current perspectives. Ann Intern Med. 1980;92:539–46.

    PubMed  CAS  Google Scholar 

  16. Alter MJ, Coleman PJ, Alexander WJ, et al. Importance of heterosexual activity in the transmission of hepatitis B and non-A, non-B hepatitis. JAMA. 1989;262:1201–5.

    PubMed  CAS  Google Scholar 

  17. Alter MJ, Gerety RJ, Smallwood LA, et al. Sporadic non-A, non-B hepatitis: frequency and epidemiology in an urban U.S. population. J Infect Dis. 1982;145:886–93.

    PubMed  CAS  Google Scholar 

  18. Cossart YE, Kirsch S, Ismay SL. Post-transfusion hepatitis in Australia. Report of the Australian Red Cross study. Lancet. 1982;1:208–13.

    PubMed  CAS  Google Scholar 

  19. Meyers JD, Dienstag JL, Purcell RH, Thomas ED, Holmes KK. Parenterally transmitted non-A, non-B hepatitis: an epidemic reassessed. Ann Intern Med. 1977;87:57–9.

    PubMed  CAS  Google Scholar 

  20. Mosley JW, Redeker AG, Feinstone SM, Purcell RH. Multiple hepatitis viruses in multiple attacks of acute viral hepatitis. N Engl J Med. 1977;296:75–8.

    PubMed  CAS  Google Scholar 

  21. Tabor E, Snoy P, Gerety RJ, Wickerhauser M, Menache D, Seeff LB. Transmission of agent of post-transfusion non-A, non-B hepatitis by cryoprecipitate prepared from plasma of symptomless chronic carrier. Lancet. 1983;1:63–4.

    PubMed  CAS  Google Scholar 

  22. Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med. 2012;156:271–8.

    PubMed  Google Scholar 

  23. Rein DB, Wittenborn JS, Weinbaum CM, Sabin M, Smith BD, Lesesne SB. Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States. Dig Liver Dis. 2011;43:66–72.

    PubMed  Google Scholar 

  24. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57:1333–42.

    PubMed  Google Scholar 

  25. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45:529–38.

    PubMed  Google Scholar 

  26. Chak E, Talal AH, Sherman KE, Schiff ER, Saab S. Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int. 2011;31:1090–101.

    PubMed  Google Scholar 

  27. Edlin BR. Hepatology. 2005;42:213A.

    Google Scholar 

  28. Institute for Health Metrics and Evaluation. Global burden of diseases, injuries, and risk factors study. Seattle: Institute for Health Metrics and Evaluation; 2010.

    Google Scholar 

  29. Chamot E, Hirschel B, Wintsch J, et al. Loss of antibodies against hepatitis C virus in HIV-seropositive intravenous drug users. AIDS. 1990;4:1275–7.

    PubMed  CAS  Google Scholar 

  30. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49:1335–74.

    PubMed  CAS  Google Scholar 

  31. Kalantar-Zadeh K, Miller LG, Daar ES. Diagnostic discordance for hepatitis C virus infection in hemodialysis patients. Am J Kidney Dis. 2005;46:290–300.

    PubMed  Google Scholar 

  32. Thio CL, Nolt KR, Astemborski J, Vlahov D, Nelson KE, Thomas DL. Screening for hepatitis C virus in human immunodeficiency virus-infected individuals. J Clin Microbiol. 2000;38:575–7.

    PubMed  CAS  PubMed Central  Google Scholar 

  33. Alter MJ, Kuhnert WL, Finelli L. Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. Centers for Disease Control and Prevention. MMWR Recomm Rep. 2003;52:1–13, 5; quiz CE1–4.

    PubMed  Google Scholar 

  34. Lemon SM, Walker C, Alter MJ, Yi M. Hepatitis C virus. In: KDaH PM, editor. Field’s virology. Philadelphia: Lippincott Williams and Wilkins; 2007. p. 1253–304.

    Google Scholar 

  35. Suzuki T, Aizaki H, Murakami K, Shoji I, Wakita T. Molecular biology of hepatitis C virus. J Gastroenterol. 2007;42:411–23.

    PubMed  CAS  Google Scholar 

  36. Chayama K, Hayes CN. Hepatitis C virus: how genetic variability affects pathobiology of disease. J Gastroenterol Hepatol. 2011;26 Suppl 1:83–95.

    PubMed  CAS  Google Scholar 

  37. Wasley A, Alter MJ. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis. 2000;20:1–16.

    PubMed  CAS  Google Scholar 

  38. Broers B, Junet C, Bourquin M, Deglon JJ, Perrin L, Hirschel B. Prevalence and incidence rate of HIV, hepatitis B and C among drug users on methadone maintenance treatment in Geneva between 1988 and 1995. AIDS. 1998;12:2059–66.

    PubMed  CAS  Google Scholar 

  39. Crofts N, Jolley D, Kaldor J, van Beek I, Wodak A. Epidemiology of hepatitis C virus infection among injecting drug users in Australia. J Epidemiol Community Health. 1997;51:692–7.

    PubMed  CAS  PubMed Central  Google Scholar 

  40. Dutta U, Raina V, Garg PK, et al. A prospective study on the incidence of hepatitis B & C infections amongst patients with lymphoproliferative disorders. Indian J Med Res. 1998;107:78–82.

    PubMed  CAS  Google Scholar 

  41. el-Ahmady O, Halim AB, Mansour O, Salman T. Incidence of hepatitis C virus in Egyptians. J Hepatol. 1994;21:687.

    PubMed  CAS  Google Scholar 

  42. Fabrizi F, Martin P, Dixit V, et al. Acquisition of hepatitis C virus in hemodialysis patients: a prospective study by branched DNA signal amplification assay. Am J Kidney Dis. 1998;31:647–54.

    PubMed  CAS  Google Scholar 

  43. Hagan H, McGough JP, Thiede H, Weiss NS, Hopkins S, Alexander ER. Syringe exchange and risk of infection with hepatitis B and C viruses. Am J Epidemiol. 1999;149:203–13.

    PubMed  CAS  Google Scholar 

  44. Tanaka E, Kiyosawa K, Sodeyama T, et al. Prevalence of antibody to hepatitis C virus in Japanese schoolchildren: comparison with adult blood donors. Am J Trop Med Hyg. 1992;46:460–4.

    PubMed  CAS  Google Scholar 

  45. van Beek I, Dwyer R, Dore GJ, Luo K, Kaldor JM. Infection with HIV and hepatitis C virus among injecting drug users in a prevention setting: retrospective cohort study. BMJ. 1998;317:433–7.

    PubMed  PubMed Central  Google Scholar 

  46. Aach RD, Stevens CE, Hollinger FB, et al. Hepatitis C virus infection in post-transfusion hepatitis. An analysis with first- and second-generation assays. N Engl J Med. 1991;325:1325–9.

    PubMed  CAS  Google Scholar 

  47. Koretz RL, Abbey H, Coleman E, Gitnick G. Non-A, non-B post-transfusion hepatitis. Looking back in the second decade. Ann Intern Med. 1993;119:110–5.

    PubMed  CAS  Google Scholar 

  48. McLaughlin KJ, Cameron SO, Good T, et al. Nosocomial transmission of hepatitis C virus within a British dialysis centre. Nephrol Dial Transplant. 1997;12:304–9.

    PubMed  CAS  Google Scholar 

  49. Niu MT, Alter MJ, Kristensen C, Margolis HS. Outbreak of hemodialysis-associated non-A, non-B hepatitis and correlation with antibody to hepatitis C virus. Am J Kidney Dis. 1992;19:345–52.

    PubMed  CAS  Google Scholar 

  50. Meng ZD, Sun YD, Chen XR, et al. A serological study of hepatitis C infection in plasmapheresis donors. Chin Med J. 1991;104:494–7.

    PubMed  CAS  Google Scholar 

  51. Rao HY, Sun DG, Yang RF, et al. Outcome of hepatitis C virus infection in Chinese paid plasma donors: a 12-19-year cohort study. J Gastroenterol Hepatol. 2012;27:526–32.

    PubMed  CAS  Google Scholar 

  52. Sun YD, Meng ZD, Wang SY, et al. Epidemiologic investigation on an outbreak of hepatitis C. Chin Med J. 1991;104:975–9.

    PubMed  CAS  Google Scholar 

  53. Centers for Disease Control and Prevention (CDC). Outbreak of hepatitis C associated with intravenous immunoglobulin administration–United States, October 1993-June 1994. MMWR Morb Mortal Wkly Rep. 1994;43:505–9.

    Google Scholar 

  54. Centers for Disease Control and Prevention. Outbreak of hepatitis C associated with intravenous immunoglobulin administration–United States, October 1993-June 1994. JAMA. 1994;272:424–5.

    Google Scholar 

  55. Bronowicki JP, Venard V, Botte C, et al. Patient-to-patient transmission of hepatitis C virus during colonoscopy. N Engl J Med. 1997;337:237–40.

    PubMed  CAS  Google Scholar 

  56. Comstock RD, Mallonee S, Fox JL, et al. A large nosocomial outbreak of hepatitis C and hepatitis B among patients receiving pain remediation treatments. Infect Control Hosp Epidemiol. 2004;25:576–83.

    PubMed  Google Scholar 

  57. Gerber AR, Englender SJ, Selvey D, et al. An outbreak of non-A, non-B hepatitis associated with the infusion of a commercial factor IX complex during cardiovascular surgery. Vox Sang. 1990;58:270–5.

    PubMed  CAS  Google Scholar 

  58. Guyer B, Bradley DW, Bryan JA, Maynard JE. Non-A, non-B hepatitis among participants in a plasmapheresis stimulation program. J Infect Dis. 1979;139:634–40.

    PubMed  CAS  Google Scholar 

  59. Krause G, Trepka MJ, Whisenhunt RS, et al. Nosocomial transmission of hepatitis C virus associated with the use of multidose saline vials. Infect Control Hosp Epidemiol. 2003;24:122–7.

    PubMed  Google Scholar 

  60. Larghi A, Zuin M, Crosignani A, et al. Outcome of an outbreak of acute hepatitis C among healthy volunteers participating in pharmacokinetics studies. Hepatology. 2002;36:993–1000.

    PubMed  CAS  Google Scholar 

  61. Morin T, Pariente A, Lahmek P, Rabaud C, Silvain C, Cadranel JF. Acute hepatitis C: analysis of a 126-case prospective, multicenter cohort. Eur J Gastroenterol Hepatol. 2010;22:157–66.

    PubMed  Google Scholar 

  62. Ross RS, Viazov S, Khudyakov YE, et al. Transmission of hepatitis C virus in an orthopedic hospital ward. J Med Virol. 2009;81:249–57.

    PubMed  CAS  Google Scholar 

  63. Savey A, Simon F, Izopet J, Lepoutre A, Fabry J, Desenclos JC. A large nosocomial outbreak of hepatitis C virus infections at a hemodialysis center. Infect Control Hosp Epidemiol. 2005;26:752–60.

    PubMed  Google Scholar 

  64. Fischer GE, Schaefer MK, Labus BJ, et al. Hepatitis C virus infections from unsafe injection practices at an endoscopy clinic in Las Vegas, Nevada, 2007-2008. Clin Infect Dis. 2010;51:267–73.

    PubMed  Google Scholar 

  65. van de Laar TJ, Matthews GV, Prins M, Danta M. Acute hepatitis C in HIV-infected men who have sex with men: an emerging sexually transmitted infection. AIDS. 2010;24:1799–812.

    PubMed  Google Scholar 

  66. Wandeler G, Gsponer T, Bregenzer A, et al. Hepatitis C virus infections in the Swiss HIV Cohort Study: a rapidly evolving epidemic. Clin Infect Dis. 2012;55:1408–16.

    PubMed  Google Scholar 

  67. Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol. 2007;13:2436–41.

    PubMed  PubMed Central  Google Scholar 

  68. Cornberg M, Razavi HA, Alberti A, et al. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int. 2011;31 Suppl 2:30–60.

    PubMed  Google Scholar 

  69. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999;341:556–62.

    PubMed  CAS  Google Scholar 

  70. Law MG, Dore GJ, Bath N, et al. Modelling hepatitis C virus incidence, prevalence and long-term sequelae in Australia, 2001. Int J Epidemiol. 2003;32:717–24.

    PubMed  Google Scholar 

  71. Capelli C, Prati D, Bosoni P, et al. Sexual transmission of hepatitis C virus to a repeat blood donor. Transfusion. 1997;37:436–40.

    PubMed  CAS  Google Scholar 

  72. Sagnelli E, Stroffolini T, Mele A, et al. The importance of HCV on the burden of chronic liver disease in Italy: a multicenter prevalence study of 9,997 cases. J Med Virol. 2005;75:522–7.

    PubMed  Google Scholar 

  73. Sun CA, Chen HC, Lu CF, et al. Transmission of hepatitis C virus in Taiwan: prevalence and risk factors based on a nationwide survey. J Med Virol. 1999;59:290–6.

    PubMed  CAS  Google Scholar 

  74. Sun CA, Chen HC, Lu SN, et al. Persistent hyperendemicity of hepatitis C virus infection in Taiwan: the important role of iatrogenic risk factors. J Med Virol. 2001;65:30–4.

    PubMed  CAS  Google Scholar 

  75. Abdel-Wahab MF, Zakaria S, Kamel M, et al. High seroprevalence of hepatitis C infection among risk groups in Egypt. Am J Trop Med Hyg. 1994;51:563–7.

    PubMed  CAS  Google Scholar 

  76. Mohamed MK, Hussein MH, Massoud AA, et al. Study of the risk factors for viral hepatitis C infection among Egyptians applying for work abroad. J Egypt Public Health Assoc. 1996;71:113–47.

    PubMed  CAS  Google Scholar 

  77. Des Jarlais DC, Diaz T, Perlis T, et al. Variability in the incidence of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus infection among young injecting drug users in New York City. Am J Epidemiol. 2003;157:467–71.

    PubMed  Google Scholar 

  78. Fuller CM, Ompad DC, Galea S, Wu Y, Koblin B, Vlahov D. Hepatitis C incidence–a comparison between injection and noninjection drug users in New York City. J Urban Health. 2004;81:20–4.

    PubMed  PubMed Central  Google Scholar 

  79. Hagan H, Thiede H, Des Jarlais DC. Hepatitis C virus infection among injection drug users: survival analysis of time to seroconversion. Epidemiology. 2004;15:543–9.

    PubMed  Google Scholar 

  80. Hahn JA, Page-Shafer K, Lum PJ, et al. Hepatitis C virus seroconversion among young injection drug users: relationships and risks. J Infect Dis. 2002;186:1558–64.

    PubMed  Google Scholar 

  81. Thorpe LE, Ouellet LJ, Hershow R, et al. Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. Am J Epidemiol. 2002;155:645–53.

    PubMed  Google Scholar 

  82. Abdel-Aziz F, Habib M, Mohamed MK, et al. Hepatitis C virus (HCV) infection in a community in the Nile Delta: population description and HCV prevalence. Hepatology. 2000;32:111–5.

    PubMed  CAS  Google Scholar 

  83. Campello C, Poli A, Dal MG, Besozzi-Valentini F. Seroprevalence, viremia and genotype distribution of hepatitis C virus: a community-based population study in northern Italy. Infection. 2002;30:7–12.

    PubMed  CAS  Google Scholar 

  84. Kamel MA, Ghaffar YA, Wasef MA, Wright M, Clark LC, Miller FD. High HCV prevalence in Egyptian blood donors. Lancet. 1992;340:427.

    PubMed  CAS  Google Scholar 

  85. Deuffic-Burban S, Mohamed MK, Larouze B, Carrat F, Valleron AJ. Expected increase in hepatitis C-related mortality in Egypt due to pre-2000 infections. J Hepatol. 2006;44:455–61.

    PubMed  Google Scholar 

  86. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997;349:825–32.

    PubMed  CAS  Google Scholar 

  87. Yu MW, Chang HC, Chang SC, et al. Role of reproductive factors in hepatocellular carcinoma: impact on hepatitis B- and C-related risk. Hepatology. 2003;38:1393–400.

    PubMed  Google Scholar 

  88. Di Martino V, Lebray P, Myers RP, et al. Progression of liver fibrosis in women infected with hepatitis C: long-term benefit of estrogen exposure. Hepatology. 2004;40:1426–33.

    PubMed  Google Scholar 

  89. Alter MJ. The epidemiology of acute and chronic hepatitis C. Clin Liver Dis. 1997;1:559–68, vi–vii.

    PubMed  CAS  Google Scholar 

  90. Lanphear BP, Linnemann Jr CC, Cannon CG, DeRonde MM, Pendy L, Kerley LM. Hepatitis C virus infection in healthcare workers: risk of exposure and infection. Infect Control Hosp Epidemiol. 1994;15:745–50.

    PubMed  CAS  Google Scholar 

  91. Puro V, Petrosillo N, Ippolito G. Risk of hepatitis C seroconversion after occupational exposures in health care workers. Italian Study Group on Occupational Risk of HIV and Other Bloodborne Infections. Am J Infect Control. 1995;23:273–7.

    PubMed  CAS  Google Scholar 

  92. Yazdanpanah Y, De Carli G, Migueres B, et al. Risk factors for hepatitis C virus transmission to health care workers after occupational exposure: a European case-control study. Clin Infect Dis. 2005;41:1423–30.

    PubMed  CAS  Google Scholar 

  93. Yazdanpanah Y, De Carli G, Migueres B, et al. Risk factors for hepatitis C virus transmission to health care workers after occupational exposure: a European case-control study. Rev Epidemiol Sante Publique. 2006;54 Spec No 1:23–31.

    Google Scholar 

  94. Klein RS, Freeman K, Taylor PE, Stevens CE. Occupational risk for hepatitis C virus infection among New York City dentists. Lancet. 1991;338:1539–42.

    PubMed  CAS  Google Scholar 

  95. Liang TJ, Ghany MG. Current and future therapies for hepatitis C virus infection. N Engl J Med. 2013;368:1907–17.

    PubMed  CAS  PubMed Central  Google Scholar 

  96. Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science. 1999;285:110–3.

    PubMed  CAS  Google Scholar 

  97. Blight KJ, Kolykhalov AA, Reed KE, Agapov EV, Rice CM. Molecular virology of hepatitis C virus: an update with respect to potential antiviral targets. Antivir Ther. 1998;3:71–81.

    PubMed  CAS  Google Scholar 

  98. Sheahan T, Jones CT, Ploss A. Advances and challenges in studying hepatitis C virus in its native environment. Expert Rev Gastroenterol Hepatol. 2010;4:541–50.

    PubMed  Google Scholar 

  99. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention. MMWR Recomm Rep. 1998;47:1–39.

    Google Scholar 

  100. Roberts EA, Yeung L. Maternal-infant transmission of hepatitis C virus infection. Hepatology. 2002;36:S106–13.

    PubMed  Google Scholar 

  101. Terrault NA. Sexual activity as a risk factor for hepatitis C. Hepatology. 2002;36:S99–105.

    PubMed  Google Scholar 

  102. Alter HJ, Purcell RH, Holland PV, Alling DW, Koziol DE. Donor transaminase and recipient hepatitis. Impact on blood transfusion services. JAMA. 1981;246:630–4.

    PubMed  CAS  Google Scholar 

  103. Donahue JG, Munoz A, Ness PM, et al. The declining risk of post-transfusion hepatitis C virus infection. N Engl J Med. 1992;327:369–73.

    PubMed  CAS  Google Scholar 

  104. Stevens CE, Aach RD, Hollinger FB, et al. Hepatitis B virus antibody in blood donors and the occurrence of non-A, non-B hepatitis in transfusion recipients. An analysis of the Transfusion-Transmitted Viruses Study. Ann Intern Med. 1984;101:733–8.

    PubMed  CAS  Google Scholar 

  105. Makris M, Preston FE, Triger DR, et al. Hepatitis C antibody and chronic liver disease in haemophilia. Lancet. 1990;335:1117–9.

    PubMed  CAS  Google Scholar 

  106. Mauser-Bunschoten EP, Bresters D, van Drimmelen AA, et al. Hepatitis C infection and viremia in Dutch hemophilia patients. J Med Virol. 1995;45:241–6.

    PubMed  CAS  Google Scholar 

  107. Pomper GJ, Wu Y, Snyder EL. Risks of transfusion-transmitted infections: 2003. Curr Opin Hematol. 2003;10:412–8.

    PubMed  Google Scholar 

  108. Hladik W, Kataaha P, Mermin J, et al. Prevalence and screening costs of hepatitis C virus among Ugandan blood donors. Trop Med Int Health. 2006;11:951–4.

    PubMed  CAS  Google Scholar 

  109. Drucker E, Alcabes PG, Marx PA. The injection century: massive unsterile injections and the emergence of human pathogens. Lancet. 2001;358:1989–92.

    PubMed  CAS  Google Scholar 

  110. Reeler AV. Injections: a fatal attraction? Soc Sci Med. 1990;31:1119–25.

    PubMed  CAS  Google Scholar 

  111. Hauri AM, Armstrong GL, Hutin YJ. The global burden of disease attributable to contaminated injections given in health care settings. Int J STD AIDS. 2004;15:7–16.

    PubMed  Google Scholar 

  112. Talaat M, Kandeel A, Rasslan O, et al. Evolution of infection control in Egypt: achievements and challenges. Am J Infect Control. 2006;34:193–200.

    PubMed  Google Scholar 

  113. Frank C, Mohamed MK, Strickland GT, et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet. 2000;355:887–91.

    PubMed  CAS  Google Scholar 

  114. Miller FD, Abu-Raddad LJ. Evidence of intense ongoing endemic transmission of hepatitis C virus in Egypt. Proc Natl Acad Sci U S A. 2010;107:14757–62.

    PubMed  PubMed Central  Google Scholar 

  115. Talaat M, el-Oun S, Kandeel A, et al. Overview of injection practices in two governorates in Egypt. Trop Med Int Health. 2003;8:234–41.

    PubMed  Google Scholar 

  116. Mathers BM, Degenhardt L, Phillips B, et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet. 2008;372:1733–45.

    PubMed  Google Scholar 

  117. Nelson PK, Mathers BM, Cowie B, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet. 2011;378:571–83.

    PubMed  PubMed Central  Google Scholar 

  118. Hagan H, Des Jarlais DC, Stern R, et al. HCV synthesis project: preliminary analyses of HCV prevalence in relation to age and duration of injection. Int J Drug Policy. 2007;18:341–51.

    PubMed  Google Scholar 

  119. Hagan H, Thiede H, Weiss NS, Hopkins SG, Duchin JS, Alexander ER. Sharing of drug preparation equipment as a risk factor for hepatitis C. Am J Public Health. 2001;91:42–6.

    PubMed  CAS  PubMed Central  Google Scholar 

  120. Thorpe L, Ouellet L, Hershow R, Bailey S, Williams II, Monerosso E. The multiperson use of non-syringe injection equipment and risk of hepatitis c infection in a cohort of young adult injection drug users, Chicago 1997–1999. Ann Epidemiol. 2000;10:472–3.

    PubMed  Google Scholar 

  121. Cavalheiro Nde P, Santos AC, Melo CE, Morimitsu SR, Barone AA. Hepatitis C virus detection in the semen of infected patients. Braz J Infect Dis. 2008;12:358–61.

    PubMed  Google Scholar 

  122. Debono E, Halfon P, Bourliere M, et al. Absence of hepatitis C genome in semen of infected men by polymerase chain reaction, branched DNA and in situ hybridization. Liver. 2000;20:257–61.

    PubMed  CAS  Google Scholar 

  123. Halfon P, Riflet H, Renou C, Quentin Y, Cacoub P. Molecular evidence of male-to-female sexual transmission of hepatitis C virus after vaginal and anal intercourse. J Clin Microbiol. 2001;39:1204–6.

    PubMed  CAS  PubMed Central  Google Scholar 

  124. Marx MA, Murugavel KG, Tarwater PM, et al. Association of hepatitis C virus infection with sexual exposure in southern India. Clin Infect Dis. 2003;37:514–20.

    PubMed  Google Scholar 

  125. Nyamathi A, Robbins WA, Fahey JL, et al. Presence and predictors of hepatitis C virus RNA in the semen of homeless men. Biol Res Nurs. 2002;4:22–30.

    PubMed  Google Scholar 

  126. Quer J, Murillo P, Esteban JI, Martell M, Esteban R, Guardia J. Sexual transmission of hepatitis C virus from a patient with chronic disease to his sex partner after removal of an intrauterine device. Sex Transm Dis. 2003;30:470–1.

    PubMed  Google Scholar 

  127. Rauch A, Rickenbach M, Weber R, et al. Unsafe sex and increased incidence of hepatitis C virus infection among HIV-infected men who have sex with men: the Swiss HIV Cohort Study. Clin Infect Dis. 2005;41:395–402.

    PubMed  Google Scholar 

  128. Urbanus AT, van de Laar TJ, Stolte IG, et al. Hepatitis C virus infections among HIV-infected men who have sex with men: an expanding epidemic. AIDS. 2009;23:F1–7.

    PubMed  Google Scholar 

  129. Leruez-Ville M, Kunstmann JM, De Almeida M, Rouzioux C, Chaix ML. Detection of hepatitis C virus in the semen of infected men. Lancet. 2000;356:42–3.

    PubMed  CAS  Google Scholar 

  130. Manavi M, Watkins-Riedel T, Kucera E, Czerwenka K, Hofmann H. Evidence of hepatitis C virus in cervical smears. J Infect. 1999;38:60–1.

    PubMed  CAS  Google Scholar 

  131. Tohme RA, Holmberg SD. Is sexual contact a major mode of hepatitis C virus transmission? Hepatology. 2010;52:1497–505.

    PubMed  Google Scholar 

  132. Frederick T, Burian P, Terrault N, et al. Factors associated with prevalent hepatitis C infection among HIV-infected women with no reported history of injection drug use: the Women’s Interagency HIV Study (WIHS). AIDS Patient Care STDS. 2009;23:915–23.

    PubMed  PubMed Central  Google Scholar 

  133. Hershow RC, Kalish LA, Sha B, Till M, Cohen M. Hepatitis C virus infection in Chicago women with or at risk for HIV infection: evidence for sexual transmission. Sex Transm Dis. 1998;25:527–32.

    PubMed  CAS  Google Scholar 

  134. Thomas DL, Zenilman JM, Alter HJ, et al. Sexual transmission of hepatitis C virus among patients attending sexually transmitted diseases clinics in Baltimore–an analysis of 309 sex partnerships. J Infect Dis. 1995;171:768–75.

    PubMed  CAS  Google Scholar 

  135. Centers for Disease Control and Prevention (CDC). Sexual transmission of hepatitis C virus among HIV-infected men who have sex with men–New York City, 2005–2010. MMWR Morb Mortal Wkly Rep. 2011;60:945–50.

    Google Scholar 

  136. Fierer DS. Epidemic of sexually transmitted hepatitis C virus infection among HIV-infected men. Curr Infect Dis Rep. 2010;12:118–25.

    PubMed  Google Scholar 

  137. Taylor LE, Holubar M, Wu K, et al. Incident hepatitis C virus infection among US HIV-infected men enrolled in clinical trials. Clin Infect Dis. 2011;52:812–8.

    PubMed  PubMed Central  Google Scholar 

  138. van de Laar T, Pybus O, Bruisten S, et al. Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men. Gastroenterology. 2009;136:1609–17.

    PubMed  Google Scholar 

  139. Hagan H, Snyder N, Hough E, et al. Case-reporting of acute hepatitis B and C among injection drug users. J Urban Health. 2002;79:579–85.

    PubMed  PubMed Central  Google Scholar 

  140. Boxall E, Baumann K, Price N, Sira J, Brown M, Kelly D. Discordant outcome of perinatal transmission of hepatitis C in twin pregnancies. J Clin Virol. 2007;38:91–5.

    PubMed  Google Scholar 

  141. Manzini P, Saracco G, Cerchier A, et al. Human immunodeficiency virus infection as risk factor for mother-to-child hepatitis C virus transmission; persistence of anti-hepatitis C virus in children is associated with the mother's anti-hepatitis C virus immunoblotting pattern. Hepatology. 1995;21:328–32.

    PubMed  CAS  Google Scholar 

  142. Mast EE, Hwang LY, Seto DS, et al. Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy. J Infect Dis. 2005;192:1880–9.

    PubMed  Google Scholar 

  143. Ohto H, Terazawa S, Sasaki N, et al. Transmission of hepatitis C virus from mothers to infants. The Vertical Transmission of Hepatitis C Virus Collaborative Study Group. N Engl J Med. 1994;330:744–50.

    PubMed  CAS  Google Scholar 

  144. Paccagnini S, Principi N, Massironi E, et al. Perinatal transmission and manifestation of hepatitis C virus infection in a high risk population. Pediatr Infect Dis J. 1995;14:195–9.

    PubMed  CAS  Google Scholar 

  145. Zanetti AR, Tanzi E, Paccagnini S, et al. Mother-to-infant transmission of hepatitis C virus. Lombardy Study Group on Vertical HCV Transmission. Lancet. 1995;345:289–91.

    PubMed  CAS  Google Scholar 

  146. Tovo PA, Palomba E, Ferraris G, et al. Increased risk of maternal-infant hepatitis C virus transmission for women coinfected with human immunodeficiency virus type 1. Italian Study Group for HCV Infection in Children. Clin Infect Dis. 1997;25:1121–4.

    PubMed  CAS  Google Scholar 

  147. Granovsky MO, Minkoff HL, Tess BH, et al. Hepatitis C virus infection in the mothers and infants cohort study. Pediatrics. 1998;102:355–9.

    PubMed  CAS  Google Scholar 

  148. Thomas DL, Villano SA, Riester KA, et al. Perinatal transmission of hepatitis C virus from human immunodeficiency virus type 1-infected mothers. Women and Infants Transmission Study. J Infect Dis. 1998;177:1480–8.

    PubMed  CAS  Google Scholar 

  149. Gibb DM, Goodall RL, Dunn DT, et al. Mother-to-child transmission of hepatitis C virus: evidence for preventable peripartum transmission. Lancet. 2000;356:904–7.

    PubMed  CAS  Google Scholar 

  150. Thomas SL, Newell ML, Peckham CS, Ades AE, Hall AJ. A review of hepatitis C virus (HCV) vertical transmission: risks of transmission to infants born to mothers with and without HCV viraemia or human immunodeficiency virus infection. Int J Epidemiol. 1998;27:108–17.

    PubMed  CAS  Google Scholar 

  151. Blackard JT, Smeaton L, Hiasa Y, et al. Detection of hepatitis C virus (HCV) in serum and peripheral-blood mononuclear cells from HCV-monoinfected and HIV/HCV-coinfected persons. J Infect Dis. 2005;192:258–65.

    PubMed  Google Scholar 

  152. Azzari C, Resti M, Moriondo M, Ferrari R, Lionetti P, Vierucci A. Vertical transmission of HCV is related to maternal peripheral blood mononuclear cell infection. Blood. 2000;96:2045–8.

    PubMed  CAS  Google Scholar 

  153. Resti M, Azzari C, Galli L, et al. Maternal drug use is a preeminent risk factor for mother-to-child hepatitis C virus transmission: results from a multicenter study of 1372 mother-infant pairs. J Infect Dis. 2002;185:567–72.

    PubMed  Google Scholar 

  154. (NIOSH) NIfOSaH. NIOSH Alert: preventing needle stick injuries in health care settings. 1999.

    Google Scholar 

  155. Beltrami EM, Kozak A, Williams IT, et al. Transmission of HIV and hepatitis C virus from a nursing home patient to a health care worker. Am J Infect Control. 2003;31:168–75.

    PubMed  Google Scholar 

  156. Alter MJ, Margolis HS, Krawczynski K, et al. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. N Engl J Med. 1992;327:1899–905.

    PubMed  CAS  Google Scholar 

  157. Lemon SM. Induction and evasion of innate antiviral responses by hepatitis C virus. J Biol Chem. 2010;285:22741–7.

    PubMed  CAS  PubMed Central  Google Scholar 

  158. Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat. 2006;13:34–41.

    PubMed  CAS  Google Scholar 

  159. Thomas DL, Astemborski J, Rai RM, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA. 2000;284:450–6.

    PubMed  CAS  Google Scholar 

  160. Maheshwari A, Ray S, Thuluvath PJ. Acute hepatitis C. Lancet. 2008;372:321–32.

    PubMed  Google Scholar 

  161. Gerlach JT, Diepolder HM, Zachoval R, et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology. 2003;125:80–8.

    PubMed  Google Scholar 

  162. Hofer H, Watkins-Riedel T, Janata O, et al. Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load. Hepatology. 2003;37:60–4.

    PubMed  Google Scholar 

  163. Villano SA, Vlahov D, Nelson KE, Cohn S, Thomas DL. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology. 1999;29:908–14.

    PubMed  CAS  Google Scholar 

  164. Seeff LB, Hoofnagle JH. National Institutes of Health Consensus Development Conference: management of hepatitis C: 2002. Hepatology. 2002;36:S1–2.

    PubMed  Google Scholar 

  165. Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009;461:798–801.

    PubMed  CAS  PubMed Central  Google Scholar 

  166. Lehmann M, Meyer MF, Monazahian M, Tillmann HL, Manns MP, Wedemeyer H. High rate of spontaneous clearance of acute hepatitis C virus genotype 3 infection. J Med Virol. 2004;73:387–91.

    PubMed  Google Scholar 

  167. Piasecki BA, Lewis JD, Reddy KR, et al. Influence of alcohol use, race, and viral coinfections on spontaneous HCV clearance in a US veteran population. Hepatology. 2004;40:892–9.

    PubMed  Google Scholar 

  168. Barrera JM, Francis B, Ercilla G, et al. Improved detection of anti-HCV in post-transfusion hepatitis by a third-generation ELISA. Vox Sang. 1995;68:15–8.

    PubMed  CAS  Google Scholar 

  169. Farci P, Alter HJ, Wong D, et al. A long-term study of hepatitis C virus replication in non-A, non-B hepatitis. N Engl J Med. 1991;325:98–104.

    PubMed  CAS  Google Scholar 

  170. Chu CM, Yeh CT, Liaw YF. Fulminant hepatic failure in acute hepatitis C: increased risk in chronic carriers of hepatitis B virus. Gut. 1999;45:613–7.

    PubMed  CAS  PubMed Central  Google Scholar 

  171. Fagan EA, Williams R. Fulminant viral hepatitis. Br Med Bull. 1990;46:462–80.

    PubMed  CAS  Google Scholar 

  172. Barkhuizen A, Rosen HR, Wolf S, Flora K, Benner K, Bennett RM. Musculoskeletal pain and fatigue are associated with chronic hepatitis C: a report of 239 hepatology clinic patients. Am J Gastroenterol. 1999;94:1355–60.

    PubMed  CAS  Google Scholar 

  173. Merican I, Sherlock S, McIntyre N, Dusheiko GM. Clinical, biochemical and histological features in 102 patients with chronic hepatitis C virus infection. Q J Med. 1993;86:119–25.

    PubMed  CAS  Google Scholar 

  174. Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci. 2006;3:47–52.

    PubMed  PubMed Central  Google Scholar 

  175. Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med. 2000;132:296–305.

    PubMed  CAS  Google Scholar 

  176. Seeff LB. Natural history of chronic hepatitis C. Hepatology. 2002;36:S35–46.

    PubMed  Google Scholar 

  177. Ryder SD, Irving WL, Jones DA, Neal KR, Underwood JC. Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study. Gut. 2004;53:451–5.

    PubMed  CAS  PubMed Central  Google Scholar 

  178. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology. 2001;33:1358–64.

    PubMed  CAS  Google Scholar 

  179. Hourigan LF, Macdonald GA, Purdie D, et al. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology. 1999;29:1215–9.

    PubMed  CAS  Google Scholar 

  180. Hu KQ, Kyulo NL, Esrailian E, et al. Overweight and obesity, hepatic steatosis, and progression of chronic hepatitis C: a retrospective study on a large cohort of patients in the United States. J Hepatol. 2004;40:147–54.

    PubMed  CAS  Google Scholar 

  181. Ong JP, Younossi ZM, Speer C, Olano A, Gramlich T, Boparai N. Chronic hepatitis C and superimposed nonalcoholic fatty liver disease. Liver. 2001;21:266–71.

    PubMed  CAS  Google Scholar 

  182. Giannini E, Mastracci L, Botta F, et al. Liver iron accumulation in chronic hepatitis C patients without HFE mutations: relationships with histological damage, viral load and genotype and alpha-glutathione S-transferase levels. Eur J Gastroenterol Hepatol. 2001;13:1355–61.

    PubMed  CAS  Google Scholar 

  183. Hezode C, Cazeneuve C, Coue O, et al. Liver iron accumulation in patients with chronic active hepatitis C: prevalence and role of hemochromatosis gene mutations and relationship with hepatic histological lesions. J Hepatol. 1999;31:979–84.

    PubMed  CAS  Google Scholar 

  184. Larson AM, Taylor SL, Bauermeister D, Rosoff Jr L, Kowdley KV. Pilot study of the relationship between histologic progression and hepatic iron concentration in chronic hepatitis C. J Clin Gastroenterol. 2003;37:406–11.

    PubMed  CAS  Google Scholar 

  185. Camma C, Bruno S, Di Marco V, et al. Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C. Hepatology. 2006;43:64–71.

    PubMed  CAS  Google Scholar 

  186. Petta S, Camma C, Di Marco V, et al. Insulin resistance and diabetes increase fibrosis in the liver of patients with genotype 1 HCV infection. Am J Gastroenterol. 2008;103:1136–44.

    PubMed  CAS  Google Scholar 

  187. Neumann UP, Berg T, Bahra M, et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol. 2004;41:830–6.

    PubMed  CAS  Google Scholar 

  188. Wali M, Harrison RF, Gow PJ, Mutimer D. Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C. Gut. 2002;51:248–52.

    PubMed  CAS  PubMed Central  Google Scholar 

  189. Charlton M. The impact of advancing donor age on histologic recurrence of hepatitis C infection: the perils of ignored maternal advice. Liver Transpl. 2003;9:535–7.

    PubMed  Google Scholar 

  190. Cortopassi GA, Wong A. Mitochondria in organismal aging and degeneration. Biochim Biophys Acta. 1999;1410:183–93.

    PubMed  CAS  Google Scholar 

  191. Shigenaga MK, Hagen TM, Ames BN. Oxidative damage and mitochondrial decay in aging. Proc Natl Acad Sci U S A. 1994;91:10771–8.

    PubMed  CAS  PubMed Central  Google Scholar 

  192. Thio CL. Host genetic factors and antiviral immune responses to hepatitis C virus. Clin Liver Dis. 2008;12:713–26, xi.

    PubMed  PubMed Central  Google Scholar 

  193. Cacciola I, Pollicino T, Squadrito G, Cerenzia G, Orlando ME, Raimondo G. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med. 1999;341:22–6.

    PubMed  CAS  Google Scholar 

  194. Roudot-Thoraval F, Bastie A, Pawlotsky JM, Dhumeaux D. Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: a French survey of 6,664 patients. The Study Group for the Prevalence and the Epidemiology of Hepatitis C Virus. Hepatology. 1997;26:485–90.

    PubMed  CAS  Google Scholar 

  195. Weber R, Sabin CA, Friis-Moller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med. 2006;166:1632–41.

    PubMed  Google Scholar 

  196. Allory Y, Charlotte F, Benhamou Y, Opolon P, Le Charpentier Y, Poynard T. Impact of human immunodeficiency virus infection on the histological features of chronic hepatitis C: a case-control study. The MULTIVIRC group. Hum Pathol. 2000;31:69–74.

    PubMed  CAS  Google Scholar 

  197. Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients, the Multivirc Group. Hepatology. 1999;30:1054–8.

    PubMed  CAS  Google Scholar 

  198. Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis. 2001;33:562–9.

    PubMed  CAS  Google Scholar 

  199. Alberti A, Pontisso P, Chemello L, et al. The interaction between hepatitis B virus and hepatitis C virus in acute and chronic liver disease. J Hepatol. 1995;22:38–41.

    PubMed  CAS  Google Scholar 

  200. Crespo J, Lozano JL, Carte B, de las Heras B, de la Cruz F, Pons-Romero F. Viral replication in patients with concomitant hepatitis B and C virus infections. Eur J Clin Microbiol Infect Dis. 1997;16:445–51.

    PubMed  CAS  Google Scholar 

  201. Ohkawa K, Hayashi N, Yuki N, et al. Hepatitis C virus antibody and hepatitis C virus replication in chronic hepatitis B patients. J Hepatol. 1994;21:509–14.

    PubMed  CAS  Google Scholar 

  202. Pontisso P, Ruvoletto MG, Fattovich G, et al. Clinical and virological profiles in patients with multiple hepatitis virus infections. Gastroenterology. 1993;105:1529–33.

    PubMed  CAS  Google Scholar 

  203. Sheen IS, Liaw YF, Chu CM, Pao CC. Role of hepatitis C virus infection in spontaneous hepatitis B surface antigen clearance during chronic hepatitis B virus infection. J Infect Dis. 1992;165:831–4.

    PubMed  CAS  Google Scholar 

  204. Squadrito G, Orlando ME, Pollicino T, et al. Virological profiles in patients with chronic hepatitis C and overt or occult HBV infection. Am J Gastroenterol. 2002;97:1518–23.

    PubMed  Google Scholar 

  205. Zarski JP, Bohn B, Bastie A, et al. Characteristics of patients with dual infection by hepatitis B and C viruses. J Hepatol. 1998;28:27–33.

    PubMed  CAS  Google Scholar 

  206. Bellecave P, Gouttenoire J, Gajer M, et al. Hepatitis B and C virus coinfection: a novel model system reveals the absence of direct viral interference. Hepatology. 2009;50:46–55.

    PubMed  CAS  Google Scholar 

  207. Eyre NS, Phillips RJ, Bowden S, et al. Hepatitis B virus and hepatitis C virus interaction in Huh-7 cells. J Hepatol. 2009;51:446–57.

    PubMed  CAS  Google Scholar 

  208. Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis. 2002;34:831–7.

    PubMed  Google Scholar 

  209. Giordano TP, Kramer JR, Souchek J, Richardson P, El-Serag HB. Cirrhosis and hepatocellular carcinoma in HIV-infected veterans with and without the hepatitis C virus: a cohort study, 1992–2001. Arch Intern Med. 2004;164:2349–54.

    PubMed  Google Scholar 

  210. Martinez-Sierra C, Arizcorreta A, Diaz F, et al. Progression of chronic hepatitis C to liver fibrosis and cirrhosis in patients coinfected with hepatitis C virus and human immunodeficiency virus. Clin Infect Dis. 2003;36:491–8.

    PubMed  Google Scholar 

  211. Merchante N, Giron-Gonzalez JA, Gonzalez-Serrano M, et al. Survival and prognostic factors of HIV-infected patients with HCV-related end-stage liver disease. AIDS. 2006;20:49–57.

    PubMed  Google Scholar 

  212. Hutchinson SJ, Bird SM, Goldberg DJ. Influence of alcohol on the progression of hepatitis C virus infection: a meta-analysis. Clin Gastroenterol Hepatol. 2005;3:1150–9.

    PubMed  Google Scholar 

  213. Monto A, Patel K, Bostrom A, et al. Risks of a range of alcohol intake on hepatitis C-related fibrosis. Hepatology. 2004;39:826–34.

    PubMed  Google Scholar 

  214. Hezode C, Roudot-Thoraval F, Nguyen S, et al. Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. Hepatology. 2005;42:63–71.

    PubMed  CAS  Google Scholar 

  215. Ishida JH, Peters MG, Jin C, et al. Influence of cannabis use on severity of hepatitis C disease. Clin Gastroenterol Hepatol. 2008;6:69–75.

    PubMed  PubMed Central  Google Scholar 

  216. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology. 2010;138:513–21, 21 e1–6.

    PubMed  Google Scholar 

  217. Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology. 1997;112:463–72.

    PubMed  CAS  Google Scholar 

  218. Planas R, Balleste B, Alvarez MA, et al. Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients. J Hepatol. 2004;40:823–30.

    PubMed  Google Scholar 

  219. Chiba T, Matsuzaki Y, Abei M, et al. Multivariate analysis of risk factors for hepatocellular carcinoma in patients with hepatitis C virus-related liver cirrhosis. J Gastroenterol. 1996;31:552–8.

    PubMed  CAS  Google Scholar 

  220. Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology. 2004;127:1372–80.

    PubMed  Google Scholar 

  221. Degos F, Christidis C, Ganne-Carrie N, et al. Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut. 2000;47:131–6.

    PubMed  CAS  PubMed Central  Google Scholar 

  222. Cacoub P, Poynard T, Ghillani P, et al. Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment virus C. Arthritis Rheum. 1999;42:2204–12.

    PubMed  CAS  Google Scholar 

  223. Jacobson IM, Cacoub P, Dal Maso L, Harrison SA, Younossi ZM. Manifestations of chronic hepatitis C virus infection beyond the liver. Clin Gastroenterol Hepatol. 2010;8:1017–29.

    PubMed  Google Scholar 

  224. Mayo MJ. Extrahepatic manifestations of hepatitis C infection. Am J Med Sci. 2003;325:135–48.

    PubMed  Google Scholar 

  225. Hagan H, Pouget ER, Des Jarlais DC. A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs. J Infect Dis. 2011;204:74–83.

    PubMed  PubMed Central  Google Scholar 

  226. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945–1965. MMWR Recomm Rep. 2012;61:1–32.

    Google Scholar 

  227. Moyer V. Screening for hepatitis C virus infection in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2013;159(5):349–57.

    Google Scholar 

  228. Strickland GT, El-Kamary SS, Klenerman P, Nicosia A. Hepatitis C vaccine: supply and demand. Lancet Infect Dis. 2008;8:379–86.

    PubMed  Google Scholar 

  229. Swadling L, Klenerman P, Barnes E. Ever closer to a prophylactic vaccine for HCV. Expert Opin Biol Ther. 2013;13(8):1109–24.

    PubMed  CAS  PubMed Central  Google Scholar 

  230. Hoofnagle JH, Mullen KD, Jones DB, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med. 1986;315:1575–8.

    PubMed  CAS  Google Scholar 

  231. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54:1433–44.

    PubMed  PubMed Central  Google Scholar 

  232. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011;364:2417–28.

    PubMed  CAS  Google Scholar 

  233. Flamm SL, Lawitz E, Jacobson I, et al. Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection. Clin Gastroenterol Hepatol. 2013;11:81 e4–7 e4; quiz e5.

    Google Scholar 

  234. Poordad F, McCone Jr J, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1195–206.

    PubMed  CAS  PubMed Central  Google Scholar 

  235. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364:2405–16.

    PubMed  CAS  Google Scholar 

  236. Fried MW, Buti M, Dore GJ et al. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study. Hepatology. 2013;58(6):1918–29. http://www.nature.com/news/united-states-to-approve-potent-oral-drugs-for-hepatitis-c-1.14059

  237. Lawitz E, Gane EJ. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;369(7):678–9

    Google Scholar 

  238. Hsu CS. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;369(7):678. doi: 10.1056/NEJMc1307641#SA1

  239. Osinusi A, Meissner EG, Lee YJ et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA. 2013;310(8):804–11

    Google Scholar 

  240. Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013;368:1867–77.

    PubMed  CAS  Google Scholar 

  241. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368:1878–87.

    PubMed  CAS  Google Scholar 

  242. Asselah T, Marcellin P. New direct-acting antivirals’ combination for the treatment of chronic hepatitis C. Liver Int. 2011;31 Suppl 1:68–77.

    PubMed  Google Scholar 

  243. Gane E. Future hepatitis C virus treatment: interferon-sparing combinations. Liver Int. 2011;31 Suppl 1:62–7.

    PubMed  Google Scholar 

  244. Ferenci PAT, Foster GR, Zeuzem S, Sarrazin C. Faldaprevir plus pegylated interferon alfa-2a and ribavirin in chronic HCV genotype-1 treatment-na€õve patients: final results from startverso1, a randomised, double-blind, placebo-controlled phase III trial. J Hepatol. 2013;58 suppl 1:S569–70.

    Google Scholar 

  245. Manns MMP, Poordad F, Affonso de Araujo S, Buti M, Horsmans Y. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype-1 infection in treatment-na€õve patients: results from QUEST-2, a phase III trial. J Hepatol. 2013;58 suppl 1:568.

    Google Scholar 

  246. Sulkowski MS, Asselah T, Lalezari J, et al. Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naive patients with chronic genotype1 HCV: SILEN-C1 trial. Hepatology. 2013;57:2143–54.

    PubMed  CAS  Google Scholar 

  247. European Paediatric Hepatitis C Virus Network. A significant sex–but not elective cesarean section–effect on mother-to-child transmission of hepatitis C virus infection. J Infect Dis. 2005;192:1872–9.

    Google Scholar 

  248. Davison SM, Mieli-Vergani G, Sira J, Kelly DA. Perinatal hepatitis C virus infection: diagnosis and management. Arch Dis Child. 2006;91:781–5.

    PubMed  CAS  PubMed Central  Google Scholar 

  249. Pruss-Ustun A, Rapiti E, Hutin Y. Estimation of the global burden of disease attributable to contaminated sharps injuries among health-care workers. Am J Ind Med. 2005;48:482–90.

    PubMed  Google Scholar 

  250. U.S. Public Health Service. Updated U.S. Public Health Service guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis. MMWR Recomm Rep. 2001;50:1–52.

    Google Scholar 

  251. Puro V, De Carli G, Cicalini S, et al. European recommendations for the management of healthcare workers occupationally exposed to hepatitis B virus and hepatitis C virus. Euro Surveill. 2005;10:260–4.

    PubMed  CAS  Google Scholar 

  252. Licata A, Di Bona D, Schepis F, Shahied L, Craxi A, Camma C. When and how to treat acute hepatitis C? J Hepatol. 2003;39:1056–62.

    PubMed  CAS  Google Scholar 

  253. Vogel W, Graziadei I, Umlauft F, et al. High-dose interferon-alpha2b treatment prevents chronicity in acute hepatitis C: a pilot study. Dig Dis Sci. 1996;41:81S–5.

    PubMed  CAS  Google Scholar 

  254. Charlton M. Hepatitis C, infection in liver transplantation. Am J Transplant. 2001;1:197–203.

    PubMed  CAS  Google Scholar 

  255. Kanwal F, Hoang T, Kramer JR, et al. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology. 2011;140:1182e1–8e1.

    Google Scholar 

  256. Shaw JJ, Shah SA. Rising incidence and demographics of hepatocellular carcinoma in the USA: what does it mean? Expert Rev Gastroenterol Hepatol. 2011;5:365–70.

    PubMed  Google Scholar 

  257. McHutchison JG, Bacon BR. Chronic hepatitis C: an age wave of disease burden. Am J Manag Care. 2005;11:S286–95; quiz S307–11.

    PubMed  Google Scholar 

  258. Roblin DW, Smith BD, Weinbaum CM, Sabin ME. HCV screening practices and prevalence in an MCO, 2000–2007. Am J Manag Care. 2011;17:548–55.

    PubMed  Google Scholar 

  259. Southern WN, Drainoni ML, Smith BD, et al. Hepatitis C testing practices and prevalence in a high-risk urban ambulatory care setting. J Viral Hepat. 2011;18:474–81.

    PubMed  CAS  PubMed Central  Google Scholar 

  260. Volk ML, Tocco R, Saini S, Lok AS. Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology. 2009;50:1750–5.

    PubMed  Google Scholar 

  261. IOM. Hepatitis and liver cancer: a national strategy for prevention and control of hepatitis B and C. Washington, DC: National Academies Press; 2010.

    Google Scholar 

  262. Heim MH. Interferons and hepatitis C virus. Swiss Med Wkly. 2012;142:w13586.

    Google Scholar 

  263. Loustaud-Ratti V, Chazouilleres O, Abergel A, Guyader D, Metivier S, Tran A, Di Martino V, Causse X, Dao T, Lucidarme D, Portal I, Cacoub P, Gournay J, Grando-Lemaire V, Hillon P, Attali P, Fontanges T, Rosa I, Petrov-Sanchez V, Barthe Y, Pawlotsky JM, Pol S, Carrat F, Bronowicki JP, CUPIC Study Group. Effectiveness of Telaprevir or Boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. Gastroenterology. 2014;147(1):132–142.

    Google Scholar 

Suggested Reading

  • Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol. 2007;13(17):2436–41.

    PubMed  PubMed Central  Google Scholar 

  • Davis GL, et al. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl. 2003;9(4):331–8.

    PubMed  Google Scholar 

  • El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142(6):1264e1–73e1.

    Google Scholar 

  • Lemon SM, Walker C, Alter MJ, Yi M. Hepatitis C virus. In: Knipe DM, Howley PM, editors. Field’s virology. Philadelphia: Lippincott Williams and Wilkins; 2007. p. 1253–304.

    Google Scholar 

  • Ly KN, et al. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med. 2012;156(4):271–8.

    PubMed  Google Scholar 

Download references

Acknowledgments

We would like to acknowledge Dr. Scott L. Friedman, Fishberg Professor of Medicine, Dean for Therapeutic Discovery and Chief, Division of Liver Diseases at Mount Sinai School of Medicine, for his review and input on this chapter.

Author information

Authors and Affiliations

  1. Division of Liver Diseases, Mount Sinai Medical Center, 1468 Madison Avenue, Annenberg Bldg, Rm 21-42, 1123, New York, NY, 10029, USA

    Ponni V. Perumalswami MD, MCR

  2. Division of Infectious Diseases, Department of Medicine, St. Luke’s and Roosevelt Hospitals, 425 West 59th Street, Suite 8B, New York, NY, USA

    Robert S. Klein MD

Authors
  1. Ponni V. Perumalswami MD, MCR
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert S. Klein MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ponni V. Perumalswami MD, MCR .

Editor information

Editors and Affiliations

  1. Department of Epidemiology, University of Alabama, Birmingham School of Public Health, Birmingham, Alabama, USA

    Richard A. Kaslow

  2. Departmant of Pediatrics, Columbia University College of Physicians and Surgeons, New York, New York, USA

    Lawrence R. Stanberry

  3. Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA

    James W. Le Duc

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media New York

About this chapter

Cite this chapter

Perumalswami, P.V., Klein, R.S. (2014). Hepatitis Viruses: Hepatitis C. In: Kaslow, R., Stanberry, L., Le Duc, J. (eds) Viral Infections of Humans. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-7448-8_33

Download citation

  • DOI: https://doi.org/10.1007/978-1-4899-7448-8_33

  • Published:

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4899-7447-1

  • Online ISBN: 978-1-4899-7448-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation